Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Genprex

Genprex
2009 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
GNPX STOCK SYMBOL
$1.72 SHARE PRICE (As of Tuesday Closing)
Description

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 100 Congress Avenue
  • Suite 2000
  • Austin, TX 78701
  • United States

+1 (512) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Genprex’s full profile, request a free trial.

Genprex Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.95 - $12.24 $26.8M $1.75 -$0.97 48.6K 15.6M

Genprex Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 13,130 16,207
Revenue 0 0 0 0
EBITDA (13,840) (12,358) (3,309) (4,131)
Net Income (13,837) (12,372) (3,314) (4,132)
Total Assets 7,476 9,269 1,260 1,911
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genprex Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Genprex‘s full profile, request access.

Request full access to PitchBook

Genprex Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Genprex‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Genprex Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agios Formerly VC-backed Cambridge, MA 000 00000 0&0
0000000 0000000000 Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
000000 00000000000 Venture Capital-Backed San Diego, CA 0 000.00 0&0
00000000000 000000 Formerly VC-backed Abingdon, United Kingdom 000 00000 00000000000 00000
000000 000000 Formerly VC-backed Seattle, WA 00 00000 000000&0 00000
To view this company’s complete list of competitors, request access »

Genprex Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Genprex‘s full profile, request access.

Request full access to PitchBook

Genprex Executive Team (6)

Name Title Board
Seat
Contact
Info
Rodney Varner JD Co-Founder, Chief Executive Officer & Chairman of the Board
Ryan Confer Chief Financial Officer
Julien Pham MD Chief Operating Officer
Pasi Antero Janne Ph.D Scientific & Medical Advisory Board
Tony Mok MD Scientific & Medical Advisory Board
You’re viewing 5 of 6 executives. Get the full list »

Genprex Board Members (4)

Name Representing Role Since Contact
Info
David Friedman JD Self Board Member 000 0000
Jack Roth MD Self Medical & Scientific Advisor and SAB Chairman 000 0000
Robert Pearson Self Board Member 000 0000
Rodney Varner JD Genprex Co-Founder, Chief Executive Officer & Chairman of the Board 000 0000